Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00081614
Status:
COMPLETED
Last Update Posted:
2014-05-16
First Post:
2004-04-15
Brief Title:
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase II Multicenter Randomized Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva Erlotinib Hydrochloride in Combination With Avastin Bevacizumab Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of the study is to assess the potential benefit of combining two targeted therapies an anti-EGF inhibitor along with an anti-VEGF inhibitor The goal will be to determine whether the addition of Erlotinib to Avastin will improve the benefit in metastatic renal cell carcinoma RCC with regard to time to progression response rate duration of response and survival compared with Avastin alone Since Avastin has been shown to be active in renal cancer the goal will be to assess whether this activity can be enhanced with Erlotinib
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None